General Anesthetic Sites on Ligand-Gated Ion Channels

描述（由申请人提供）：在美国，每年约有2500万患者使用治疗指数非常低的药物进行全身麻醉。 全身麻醉的分子机制仍然未知，阻碍了改进药物的设计。 全身麻醉剂作用于配体门控通道的超家族，所述配体门控通道包括由GABA和甘氨酸门控的抑制性阴离子通道以及由5-羟色胺和乙酰胆碱门控的兴奋性阳离子通道。 本PPG侧重于 全身麻醉剂增强抑制性GABAA受体（GABAAR）的活性和抑制（在某些情况下增强）兴奋性神经元5-羟色胺（5-HT 3R）和烟碱乙酰胆碱受体（nAcChoR）的能力。 总的假设是，全身麻醉药的各种作用是由这些受体上的许多结合位点介导的，它们的位置和亲和力随麻醉剂的结构和受体的构象而变化，并且两种同源受体之间存在相似之处。 PPG的总体目标是：（i）定位GABAA、5-HT 3和nAcCho受体上的麻醉剂结合位点，以及（ii）定义每个位点的功能意义。 将采用两种互补技术检测位点，即光亲和标记（项目2、3和5）和定点诱变（项目1、3、4和5）。 项目1将描述5-HT 3受体的药理学特征，并与项目2和3相互作用，项目2和3将定位醇、依托咪酯和丙泊酚光标记的激活（时间分辨光标记）和脱敏受体状态的作用位点。 项目4将使用快速灌注膜片钳技术在野生型和突变受体中详细定义麻醉剂对GABAAR作用的动力学机制，并结合光标记结果来指导诱变和解释。 项目5将使用光活化全身麻醉药在GABAA受体上定位全身麻醉部位。 合成和蛋白质化学核心是必不可少的开发新的光亲和性全身麻醉药和定位网站的光掺入，分别。 蛋白质生产核心将为每个项目提供神经元受体。

DESCRIPTION (provided by applicant): Some 25 million patients are given general anesthesia each year in the USA using agents with very low therapeutic indices. The molecular mechanisms of general anesthesia remain unknown, hampering the design of improved agents. General anesthetics act on a superfamily of ligand gated channels which include inhibitory anion channels gated by GABA and glycine, and excitatory cation channels gated by serotonin and acetylcholine. This PPG focuses on the ability of general anesthetics to enhance the activity of the inhibitory GABAA receptor (GABAAR) and to inhibit (and in some cases enhance) the excitatory neuronal serotonin (5-HT3R) and nicotinic acetylcholine receptors (nAcChoR). The overall hypothesis is that the various action of general anesthetics are mediated by a number of binding sites on these receptors, that their location and affinity varies with the anesthetic's structure and the receptor's conformation, and that parallels exist between the two homologous receptors. The overall aims of the PPG are to: (i) locate anesthetic binding sites on the GABAA, 5-HT3 and nAcCho receptors, and (ii) define the functional significance of each site. Two complementary techniques will be employed to detect sites, photoaffinity labeling (Projects 2, 3 and 5) and site directed mutagenesis (Projects 1, 3, 4 and 5). Project 1 will characterize the pharmacology of the 5-HT3 receptor and interact with Projects 2 and 3 who will locate the sites of action on activated (time-resolved photolabeling) and desensitized receptor states of alcohols, etomidate and propofol photolabels. Project 4 will define in detail the kinetic mechanisms of anesthetic action on GABAARs using rapid perfusion patch clamp techniques in wild type and mutated receptors, incorporating the photolabeling results to guide mutagenesis and interpretation. Project 5 will locate general anesthetic sites on GABAA receptors using photoactivable general anesthetics. Synthetic and Protein Chemistry Cores are essential for developing novel photoaffinity general anesthetics and for locating the sites of photoincorporation, respectively. A Protein Production Core will supply neuronal receptors to each of the projects.